Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016971 · ClinicalTrials.gov registry record · Phase 1
CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07016971 is a Phase 1 study that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT07016971, a Phase 1 study, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)/cannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adults who have completed platinum-based chemotherapy for gastrointestinal cancers. The main questions it aims to answer are: Is CBG/CBD oil safe and well-tolerated over a 12-week treatment period? Can participants with CIPN use CBG/CBD oil consistently as part of their care? Does CBG/CBD oil help reduce pain, numbness, or other symptoms of CIPN? Participants will: Take CBG/CBD oil under the tongue (sublingually) twice daily for 12 weeks Complete regular symptom assessments and functional tests during study visits Provide blood samples for cannabinoid and metabolite level testing
Interventions
- DRUG CBG/CBD Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-04-03 |
| Est. Completion | 2029-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016971
The ClinicalTrials.gov registry entry for NCT07016971 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBG/CBD Oil is the first listed.
NCT07016971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07016971 about?
NCT07016971 is a clinical study titled "CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy". The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)/cannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adults who have completed platinum-based chemotherapy for gastrointestinal c...
What is the current status of trial NCT07016971?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-04-03. Estimated completion is 2029-07-03.
What interventions are being tested in trial NCT07016971?
The interventions under investigation include: CBG/CBD Oil (DRUG).
Who is sponsoring clinical trial NCT07016971?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.